Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug entry refers to a co-administration regimen involving a live-attenuated measles, mumps, and rubella (MMR) vaccine and a live-attenuated yellow fever vaccine. Developed and evaluated by Sanofi, the regimen specifically focuses on the investigational Vero-cell derived yellow fever vaccine (vYF) compared to licensed egg-derived counterparts like Stamaril and YF-VAX. The combination is intended for pediatric populations, particularly infants and children aged 9 months to 5 years, to provide synchronized protection against measles, mumps, rubella, and yellow fever. Clinical evaluation in Phase III trials (such as VYF04) aims to demonstrate that simultaneous administration maintains the safety and immunogenicity of each individual component without interference.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles + mumps + rubella vaccine + yellow fever vaccine.